Document is current
Any future updates will be listed below
-
Authors
Matta, Joane https://orcid.org/0000-0002-9123-6726
Robineau, Olivier
Wiernik, Emmanuel https://orcid.org/0000-0001-8046-7919
Carrat, Fabrice
Severi, Gianluca
Touvier, Mathilde https://orcid.org/0000-0002-8322-8857
Gouraud, Clément
Ouazana Vedrines, Charles https://orcid.org/0000-0002-3587-7182
Pitron, Victor
Ranque, Brigitte
Pignon, Baptiste
Hoertel, Nicolas
Kab, Sofiane
Goldberg, Marcel https://orcid.org/0000-0002-6161-5880
Zins, Marie https://orcid.org/0000-0002-4540-4282
Lemogne, Cédric https://orcid.org/0000-0002-3487-4721
- License Information
-
More Information
Article History
Received: 9 February 2023
Revised: 9 June 2023
Accepted: 3 July 2023
First Online: 19 July 2023
Competing interests
: Dr Robineau reported personal fees and nonfinancial support from Gilead, ViiV Healthcare, and Merck Sharp & Dohme Corp outside the submitted work. Dr Pitron reported personal fees from Grunenthal, outside the submitted work. Dr Lemogne reported non-financial support from Nordic Pharma, outside the submitted work. No other disclosures were reported.
